Haenen Vincent, Evenepoel Margaux, De Baerdemaecker Tom, Meeus Mira, Devoogdt Nele, Morlion Bart, Dams Lore, Van Dijck Sophie, Van der Gucht Elien, De Vrieze Tessa, Vyvere Thijs Vande, De Groef An
Department of Rehabilitation Sciences and Physiotherapy, MOVANT, University of Antwerp, Antwerp, Belgium.
Department of Rehabilitation Sciences, KU Leuven, University of Leuven, Leuven, Belgium.
Support Care Cancer. 2022 Dec 27;31(1):85. doi: 10.1007/s00520-022-07491-8.
The latest systematic review on the prevalence of pain in cancer survivors was published 5 years ago. The current review aims to provide an extended overview on the prevalence of pain, pain mechanisms, pain characteristics, and assessment methods in cancer survivors.
A systematic research was conducted on 17th of April 2020 using MEDLINE, Embase, Scopus, Web of Science, and Cochrane looking at studies from 2014 to 2020. Studies had to report pain prevalence rates in cancer survivors with a solid tumor who finished curative treatment at least 3 months ago. Methodological quality was assessed by two independent reviewers using the Joanna Briggs Institute quality appraisal tool. Characteristics of the included studies, participants and reported pain prevalence rates were extracted. The reported prevalence rates of the individual studies were pooled within a meta-analysis. Meta-regressions were performed to identify possible determinants of the pooled pain prevalence.
After deduplication, 7300 articles were screened, after which 38 were included in the meta-analysis. Risk of bias was rated low in 26 articles and moderate in 12 articles. The pooled pain prevalence was 47% (95%CI 39-55), with a heterogeneity of 98.99%.
This meta-analysis suggests that nearly half of cancer survivors report pain after completing curative treatment at least 3 months ago. However, substantial unexplained heterogeneity warrants cautious interpretation of these results. Meta-regression using cancer type, treatment location, pain measurement, and follow-up time as a covariate could not explain influencing factors explaining the high heterogeneity.
关于癌症幸存者疼痛患病率的最新系统评价发表于5年前。本综述旨在对癌症幸存者的疼痛患病率、疼痛机制、疼痛特征及评估方法提供更全面的概述。
于2020年4月17日使用MEDLINE、Embase、Scopus、Web of Science和Cochrane进行系统研究，检索2014年至2020年的研究。研究必须报告至少在3个月前完成根治性治疗的实体瘤癌症幸存者的疼痛患病率。由两名独立评审员使用乔安娜·布里格斯研究所质量评估工具评估方法学质量。提取纳入研究的特征、参与者及报告的疼痛患病率。将各研究报告的患病率汇总进行荟萃分析。进行荟萃回归以确定汇总疼痛患病率的可能决定因素。
在去除重复项后，筛选了7300篇文章，其中38篇纳入荟萃分析。26篇文章的偏倚风险被评为低，12篇为中等。汇总疼痛患病率为47%（95%CI 39 - 55），异质性为98.99%。
这项荟萃分析表明，近一半的癌症幸存者在至少3个月前完成根治性治疗后报告有疼痛。然而，大量无法解释的异质性使得对这些结果的解释需谨慎。以癌症类型、治疗部位、疼痛测量和随访时间作为协变量的荟萃回归无法解释导致高异质性的影响因素。
